In a study released today at the Society of Gynecologic Oncologists 37th Annual Meeting on Women's Cancer, researchers found the addition of thalidomide to topotecan for the treatment of recurrent ovarian cancer significantly increases the response to therapy and the duration of progression free survival without additional toxicity.

The study, "A Prospective Randomized Trial of Thalidomide with Topotecan Compared to Topotecan Alone in Women with Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma," was led by Levi S. Downs Jr., M.D., University of Minnesota Medical School and Cancer Center, Minneapolis, MN.

"This trial is among the first to combine a biologic agent with a conventional chemotherapy agent for the treatment of ovarian cancer," said the study's lead author, Dr. Levi S. Downs, Jr. "The statistically significant improvement in overall response rate demonstrated in this experimental treatment is promising as we continue to seek better therapies to fight ovarian cancer."

Thalidomide is a biologic therapy that may fight tumors in two ways: First by inhibiting the tumors ability to generate new blood vessels to feed a growing mass of cells and second by boosting the immune response to the abnormal tumor cells. Biologic therapies are intended to work with the body's natural defenses to help fight tumor cells without harming healthy cells; these therapies hold promise for effectiveness without the extreme toxicities seen in conventional chemotherapy.

This randomized trial involved women from seven different research sites (although a majority were from one institution) who had recurrent or persistent epithelial ovarian carcinoma. The final analysis included 39 women in the topotecan/control arm and 30 women in the thalidomide/topotecan arm. The women in the thalidomide/topotecan arm:

• Had a 47 percent overall response rate compared to 21 percent in the control arm; and
• Ha
  '"/>

Contact: Jennifer Grunstad
jgrunstad@thegcf.org
312-282-0627
Society of Gynecologic Oncologists
24-Mar-2006


Page: 1 2
Related medicine news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. New study counts the economic cost of persistent pain in Australia
5. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
6. Most seniors now have drug coverage, U-M study shows
7. To gain muscle and lose fat, drink milk: study
8. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
9. Even older women at high risk have little interest in being tested for HIV, study finds
10. Metabolic study in mice could lead to good cholesterol boosters
11. Michigan-CDC study supports value of social restrictions during influenza pandemics